MiNK Therapeutics to Participate at BTIG Biotechnology Conference
MiNK Therapeutics, a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies for cancer and immune-mediated diseases, will attend the BTIG 2022 Biotechnology Conference. The company will participate virtually and conduct one-on-one meetings with investors on August 8th and 9th. MiNK is advancing both native and engineered iNKT programs, focusing on scalable and reproducible manufacturing for off-the-shelf delivery. For more details, visit their website at minktherapeutics.com.
- None.
- None.
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will attend the BTIG 2022 Biotechnology Conference. MiNK will participate virtually and host one-on-one meetings with investors on August 8th and 9th.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Contact
Kimberly Ha
KKH Advisors
917-291-5744
FAQ
What is MiNK Therapeutics participating in on August 8th and 9th, 2022?
What type of therapies does MiNK Therapeutics develop?
Where is MiNK Therapeutics headquartered?
What are the key features of MiNK's iNKT therapies?
How can I find more information about MiNK Therapeutics?
